SCHEMBL356843

SCHEMBL356843

Fc1cn(C2CCN(c3ncc(OC(F)F)cn3)CC2)c2ncnc(Cl)c12

nearest known ligand 0.32

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 2/20 0.32
KCNH2 Q12809 1/20 0.32
NR1H2 P55055 1/20 0.30
NR1H3 Q13133 1/20 0.30
KIT P10721 1/20 0.30
RIPK2 O43353 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL354783 0.86 RIPK2 (0.35) GPR119KITRIPK2
SCHEMBL358364 0.86 GPR119 (0.36) GPR119KCNH2KITRIPK2
SCHEMBL356834 0.84 RIPK2 (0.32) GPR119KCNH2KITRIPK2
SCHEMBL357038 0.84 RIPK2 (0.38) GPR119KCNH2KITRIPK2
SCHEMBL356951 0.83 RIPK2 (0.32) GPR119KCNH2KITRIPK2
SCHEMBL10140747 0.82 MALT1 (0.37) KCNH2KITRIPK2
SCHEMBL355735 0.82 GPR119 (0.40) GPR119RIPK2
SCHEMBL354786 0.81 GPR119 (0.40) GPR119
SCHEMBL356620 0.80 GPR119 (0.45) GPR119
SCHEMBL355724 0.77 GPR119 (0.40) GPR119KITRIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 US disclosed
EP-2390254-A1 NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2011-11-30 EP disclosed
US-20110257678-A1 VASCULAR EMBOLIC FILTER EXCHANGE DEVICES AND METHODS OF USE THEREOF INCEPT LLC (US) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND GPR119, GPR139, HCAR1 GPR119 1/4885KCNH2 598/4885NR1H2 330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.